Drug tested to shrink tumors before cancer surgery
NCT ID NCT00954226
Summary
This early-phase study tested whether giving the drug erlotinib for a few weeks before surgery could help patients with recurrent head and neck cancer. The trial involved 48 participants who were scheduled for surgery and aimed to see how different doses of the drug affected cancer cells and to check for safety. The main goal was to understand the drug's biological effects on the tumor, not to provide a curative treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.